LundImmunotalks Seminar

Get ready for an engaging dive into the world of immuno-oncology at the upcoming LundImmunotalks seminar. We’re thrilled to offer a unique perspective into the path towards clinical applications during the talk by two globally distinguished clinical experts.

Meet Our Speakers: 

• Joshua Brody, who heads the Lymphoma Immunotherapy Program at The Tisch Cancer Institute in Mount Sinai, New York. Joshua Brody will talk about teaching our patients’ T cells how to target their own tumor antigens and how to overcome antigen escape.
• Ulrich Lauer, serving as Deputy Director of Internal Medicine, Medical Oncology, and Pneumology at University Hospital Tübingen, Germany. Ulrich Lauer will talk about personalized virotherapy.

In addition to insightful talks, take advantage of the networking Fika session, sponsored by Miltenyi. Make sure not to miss this opportunity to acquire a deeper understanding of the real-world utilization of immuno-oncology in clinical contexts!

Speakers:

• Joshua Brody is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a member of several organizations including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology. Dr. Brody has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that activates professional antigen presenting cells to induce anti-tumor immunity at the tumor site and in addition can cause regression of tumors throughout the body. Joshua Brody received his BA in Biochemistry at Harvard University, MD at Stony Brook University, performed his residency in Internal Medicine at Yale New Haven Hospital, and Fellowship in Medical Oncology at Stanford.
• Ulrich Lauer completed his medical education at the University of Erlangen-Nuernberg, performed a residency in internal medicine and an oncology fellowship at the University of Tuebingen. He pursued postdoctoral training at the Department of Virus Research within the Max-Planck-Institute for Biochemistry, specializing in pioneering virotherapy for solid tumors and gene therapy for monogenetic disorders. Since 2006, he has led the German Oncolysis Consortium (GOC) and notably conducted the first German clinical virotherapy trial from 2012 to 2014, introducing a groundbreaking recombinant oncolytic virus. Prof. Lauer directs the Virotherapy Center Tübingen (VCT), serves as Deputy Director of Internal Medicine VIII, overseeing the Department of Medical Oncology and Pneumology, and leads the Phase I Clinical Study Unit / Early Clinical Trial Unit (ECTU) at the University Hospital Tübingen. Further, he contributes as a medical oncologist at the German National Center for Tumor Diseases SouthWest (NCT-SW) and heads the European Neuroendocrine Tumor Society Center of Excellence Tuebingen (ENETS). Furthermore, Prof. Lauer is a Member of the Task Force Technology Transfer and a Member of the Ethics Committee of the Medical Faculty of the Eberhard-Karls- University Tübingen and the University Hospital Tübingen.